Search results for "DISCOVERY"

showing 10 items of 4119 documents

Design, synthesis, and biological evaluation of a new class of benzo[b]furan derivatives as antiproliferative agents, with in silico predicted antitu…

2018

A new series of 3-benzoylamino-5-(1H-imidazol-4-yl)methylaminobenzo[b]furans were synthesized and screened as antitumor agents. As a general trend, tested compounds showed concentration-dependent antiproliferative activity against HeLa and MCF-7 cancer cell lines, exhibiting GI50 values in the low micromolar range. In most cases, insertion of a methyl substituent on the imidazole moiety improved the antiproliferative activity. Therefore, methyl-imidazolyl-benzo[b]furans compounds were tested in cell cycle perturbation experiments, producing cell cycle arrest with proapoptotic effects. Their core similarity to known colchicine binding site binders led us to further study the structure featur…

0301 basic medicineCell cycle checkpointinduced fit docking studieantitubulin agents01 natural sciencesBiochemistryHeLa and MCF-7 cell linesHeLachemistry.chemical_compoundTubulinFuranDrug DiscoveryImidazoleMoietybiologyHeLa and MCF-7 cell lineG2/M phaseTubulin ModulatorsMolecular Docking SimulationAntiproliferative AgentsMCF-7 CellsMolecular MedicineVLAK protocolantitubulin agentStereochemistryIn silicoSubstituent3-benzoylamino-5-(1H-imidazol-4-yl)methylaminobenzo[b]furansAntineoplastic Agentsinduced fit docking studiesantitumor agents03 medical and health sciencesHumanscolchicine binding siteBenzofuransCell ProliferationPharmacologyBinding Sites010405 organic chemistryOrganic ChemistryCell Cycle Checkpoints3-benzoylamino-5-(1H-imidazol-4-yl)methylaminobenzo[b]furanbiology.organism_classification0104 chemical sciencesProtein Structure Tertiary030104 developmental biologychemistryantitumor agentDrug DesignColchicineHeLa Cells
researchProduct

Repurposing of Drugs Targeting YAP-TEAD Functions

2018

Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be rele…

0301 basic medicineCell signalingCell signalingCancer ResearchProtein-protein interactionsHippo pathwayDrug repurposingprotein-protein interactionsComputational biologyReviewBiologylcsh:RC254-28203 medical and health sciencesYAP-TEAD disruptioncell signalingRepurposingTissue homeostasisHippo signaling pathwaydrug repurposingEffectorCell growthDrug discoveryYap-tead disruptionlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDrug repositioning030104 developmental biologyOncologyCell signaling; Drug repurposing; Hippo pathway; Protein-protein interactions; Yap-tead disruption; Oncology; Cancer ResearchCancers
researchProduct

Anti-Oxidant, Anti-Inflammatory and Anti-Angiogenic Properties of Resveratrol in Ocular Diseases

2016

International audience; Resveratrol (3,4,5 trihydroxy-trans-stilbene) is one of the best known phytophenols with pleiotropic properties. It is a phytoalexin produced by vine and it leads to the stimulation of natural plant defenses but also exhibits many beneficial effects in animals and humans by acting on a wide range of organs and tissues. These include the prevention of cardiovascular diseases, anti-cancer potential, neuroprotective effects, homeostasia maintenance, aging delay and a decrease in inflammation. Age-related macular degeneration (AMD) is one of the main causes of deterioration of vision in adults in developed countries This review deals with resveratrol and ophthalmology by…

0301 basic medicineCell typeAntioxidantEye Diseasesmedicine.drug_classmedicine.medical_treatmentAnti-Inflammatory AgentsDrug Evaluation PreclinicalPharmaceutical ScienceAngiogenesis InhibitorsInflammationReviewPharmacologyBiologyResveratrolresveratrolNeuroprotectionAntioxidantsAnti-inflammatoryAnalytical Chemistrylcsh:QD241-44103 medical and health scienceschemistry.chemical_compoundImmune systemlcsh:Organic chemistry[ CHIM.ORGA ] Chemical Sciences/Organic chemistryStilbenesDrug DiscoverymedicineAnimalsHumansPhysical and Theoretical Chemistrychemistry.chemical_classificationPhytoalexinOrganic ChemistryeyesDisease Models Animal030104 developmental biologyGene Expression RegulationchemistryBiochemistryChemistry (miscellaneous)inflammation[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansMolecular Medicinemedicine.symptom
researchProduct

Cytotoxic benzylbenzofuran derivatives from Dorstenia kameruniana

2018

Abstract Chromatographic separation of the extract of the roots of Dorstenia kameruniana (family Moraceae) led to the isolation of three new benzylbenzofuran derivatives, 2-(p-hydroxybenzyl)benzofuran-6-ol (1), 2-(p-hydroxybenzyl)-7-methoxybenzofuran-6-ol (2) and 2-(p-hydroxy)-3-(3-methylbut-2-en-1-yl)benzyl)benzofuran-6-ol(3) (named dorsmerunin A, B and C, respectively), along with the known furanocoumarin, bergapten (4). The twigs of Dorstenia kameruniana also produced compounds 1–4 as well as the known chalcone licoagrochalcone A (5). The structures were elucidated by NMR spectroscopy and mass spectrometry. The isolated compounds displayed cytotoxicity against the sensitive CCRF-CEM and …

0301 basic medicineChalconeStereochemistryMoraceaeBergapten03 medical and health sciencesFuranocoumarinchemistry.chemical_compound0302 clinical medicineCell Line TumorDrug DiscoveryHumansCytotoxicityIC50Institut für Biochemie und BiologieBenzofuransPharmacologyMolecular StructurebiologyGeneral MedicineNuclear magnetic resonance spectroscopyMoraceaebiology.organism_classificationAntineoplastic Agents PhytogenicDrug Resistance Multiple030104 developmental biologychemistryDrug Resistance NeoplasmCell culture030220 oncology & carcinogenesisddc:540Fitoterapia
researchProduct

Alzheimer's Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy

2016

Background: Alzheimer’s disease (AD) is a dementia, a neurodegenerative condition, and a protein-misfolding disease or proteinopathy, characterized by protein deposits, extracellular plaques and intracellular neurofibrillary tangles, which contain the AD’s typical pathological proteins, abnormal [1]-amyloid and hyperphosphorylated tau, respectively, and are located predominantly in the cortex of the frontal, parietal, and temporal brain lobes. What is the role of molecular chaperones in AD? Data indicate that molecular chaperones, also known as Hsp, are involved in AD, probably displaying protective roles and/or acting as pathogenic factors as it occurs in chaperonopathies in which case AD …

0301 basic medicineChaperonotherapyDisease03 medical and health sciencesAlzheimer DiseaseDrug DiscoveryProtein-misfolding diseasemedicineExtracellularAnimalsHumansDementiaAlzheimer’s disease; Chaperonopathies; Chaperonotherapy; Molecular chaperones; Protein-misfolding diseases; Tau; β-amyloid; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceGenePharmacologybiologyβ-amyloidDrug Discovery3003 Pharmaceutical Sciencemedicine.diseaseHsp90030104 developmental biologyChaperone (protein)ImmunologyChaperonopathieMolecular chaperonebiology.proteinHSP60TauAlzheimer’s diseaseNeuroscienceIntracellularMolecular ChaperonesCurrent Pharmaceutical Design
researchProduct

Anti-inflammatory tetraquinane diterpenoids from a Crinipellis species.

2016

The small pro-inflammatory 10kDa chemokine CXCL10 (Interferon-inducible protein 10, IP-10) plays an important role in mediating immune responses through the activation and recruitment of leukocytes such as T cells, eosinophils, monocytes and NK cells to the sites of inflammation. Elevated levels of CXCL10 have been associated with chronic inflammatory and infectious diseases and therefore CXCL10 represents an attractive target for the development of new anti-inflammatory drugs. In a search for anti-inflammatory compounds from fungi inhibiting the inducible CXCL10 promoter activity, four new tetraquinane diterpenoids, crinipellin E (1), crinipellin F (2), crinipellin G (3) and crinipellin H …

0301 basic medicineChemokinemedicine.drug_classClinical BiochemistryPharmaceutical ScienceInflammation010402 general chemistry01 natural sciencesBiochemistryAnti-inflammatory03 medical and health sciencesStructure-Activity RelationshipImmune systemDrug DiscoverymedicineCXCL10HumansMolecular BiologyCells CulturedbiologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryAnti-Inflammatory Agents Non-SteroidalBiological activityNuclear magnetic resonance spectroscopyTransfectionMolecular biology0104 chemical sciencesChemokine CXCL10030104 developmental biologyBiochemistrybiology.proteinMolecular Medicinemedicine.symptomDiterpenesAgaricalesBioorganicmedicinal chemistry
researchProduct

Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences

2016

Chronic respiratory diseases affect millions of people every day. According to the World Health Organization estimates, ~235 million people suffer from asthma, ~64 million suffer from chronic obstructive pulmonary disease (COPD), and millions more suffer from allergic rhinitis around the world. In recent last years, the first phosphodiesterase 4 (PDE4) inhibitor, roflumilast, was approved as a treatment to reduce the risk of exacerbations in stable and severe COPD associated with chronic bronchitis and a history of exacerbations. PDE4 exists as four subtypes (A, B, C, and D) each with a capacity to degrade cAMP, a second messenger involved in inflammatory responses. PDE4 inhibitors inhibit …

0301 basic medicineChronic bronchitisPhosphodiesterase InhibitorsPharmacologyPulmonary Disease Chronic Obstructive03 medical and health sciencesPDE4BDrug DiscoverymedicineAnimalsHumansRespiratory systemRoflumilastAsthmaPharmacologyCOPDPhosphoric Diester Hydrolasesbusiness.industryPhosphodiesterasemedicine.diseaseIsoenzymesDiarrhea030104 developmental biologymedicine.symptombusinessmedicine.drugCurrent Pharmaceutical Design
researchProduct

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells

2017

AbstractWe have used a computational approach to identify anti-fibrotic therapies by querying a transcriptome. A transcriptome signature of activated hepatic stellate cells (HSCs), the primary collagen-secreting cell in liver, and queried against a transcriptomic database that quantifies changes in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap). The flavonoid apigenin was among 9 top-ranked compounds predicted to have anti-fibrotic activity; indeed, apigenin dose-dependently reduced collagen I in the human HSC line, TWNT-4. To identify proteins mediating apigenin’s effect, we next overlapped a 122-gene signature unique to HSCs with a list of 160 genes encoding…

0301 basic medicineCirrhosisCellPharmacologyBiologyArticleCell LineTranscriptome03 medical and health scienceschemistry.chemical_compoundMiceDrug DiscoverymedicineHepatic Stellate CellsAnimalsHumansApigeninMultidisciplinaryDrug Repositioningmedicine.diseaseHepatic stellate cell activationAntifibrinolytic Agents3. Good health030104 developmental biologymedicine.anatomical_structurechemistryCell cultureApigeninHepatic stellate cellHepatic fibrosisTranscriptomeBiomarkersScientific Reports
researchProduct

Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand?

2016

Inflammatory diseases affect a large portion of the worldwide population, and chronic inflammation is a major risk factor for several dangerous pathologies. To limit the side effects of both synthetic and biological anti-inflammatory drugs, the use of herbal medicines, nutraceuticals and food supplements has increased tremendously as alternative and/or complementary medicine to treat several pathologies, including inflammation. During the last decades, the biological properties of Citrus bergamia (bergamot) derivatives have obtained important scientific achievements, and it has been suggested their use in a context of a multitarget pharmacological strategy. Here, we present an overview of t…

0301 basic medicineCitrusnatural productsAnti-Inflammatory AgentsCitruantioxidant activityPharmaceutical SciencebergamotReviewPharmacologyAnalytical Chemistry0302 clinical medicinecomplementary and alternative medicinesDrug DiscoveryCitrus bergamiaeducation.field_of_studyTraditional medicineMedicine (all)3. Good healthAnti-Inflammatory AgentChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineComplementary medicineHumanmedicine.drug_classHerbal MedicinePopulationContext (language use)Natural productAnti-inflammatoryPlant ExtractAntioxidant activity; Bergamot; Citrus bergamia; Complementary and alternative medicines; Flavonoids; Inflammation; Natural products; Anti-Inflammatory Agents; Citrus; Herbal Medicine; Humans; Inflammation; Plant Extracts; Organic Chemistrylcsh:QD241-44103 medical and health sciencesNutraceuticallcsh:Organic chemistrySettore MED/43 - Medicina LegaleBiological propertymedicineHumansPhysical and Theoretical ChemistryeducationAntioxidant activity Bergamot Citrus bergamia Complementary and alternative medicines Flavonoids Inflammation Natural products Medicine (all);Plant Extractsbusiness.industryOrganic Chemistry030104 developmental biologyComplementary and alternative medicineinflammationflavonoidsCitrus bergamiaFlavonoidSettore BIO/14 - FarmacologiabusinessMolecules
researchProduct

The potential of aldehyde dehydrogenase 2 as a therapeutic target in cardiovascular disease.

2018

Mitochondrial aldehyde dehydrogenase (ALDH-2) plays a major role in the ethanol detoxification pathway by removing acetaldehyde. Therefore, ALDH-2 inhibitors such as disulfiram represent the first therapeutic targeting of ALDH-2 for alcoholism therapy. Areas covered: Recently, ALDH-2 was identified as an essential bioactivating enzyme of the anti-ischemic organic nitrate nitroglycerin, bringing ALDH-2 again into the focus of clinical interest. Mechanistic studies on the nitroglycerin bioactivation process revealed that during bioconversion of nitroglycerin and in the presence of reactive oxygen and nitrogen species the active site thiols of ALDH-2 are oxidized and the enzyme activity is los…

0301 basic medicineClinical BiochemistryAldehyde dehydrogenasemedicine.disease_causeAntioxidants03 medical and health scienceschemistry.chemical_compoundDetoxificationDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyPharmacologyEthanolbiologyAldehyde Dehydrogenase MitochondrialMitochondrial Aldehyde DehydrogenaseAcetaldehydeCardiovascular AgentsDisease Models AnimalOxidative Stress030104 developmental biologyBiochemistrychemistryCardiovascular DiseasesDrug DesignCardiovascular agentDisulfirambiology.proteinMolecular MedicineOxidative stressmedicine.drugExpert opinion on therapeutic targets
researchProduct